Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

Eli Lilly raises 2026 outlook again as Q2 soars past estimates

Aug 6, 2026, 10:18 AM

Read Full Article → Eli Lilly raises 2026 outlook again as Q2 soars past estimates

Eli Lilly raises 2026 outlook again as Q2 soars past estimates

Translate article text

Choose a language and wait for the translated text.

Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.

Eli Lilly raises 2026 outlook again as Q2 soars past estimates | PharmaVoice